On July 23, 2018 Veracyte, Inc. (Nasdaq: VCYT) reported financial results for the second quarter ended June 30, 2018 and provided an update on recent business progress (Press release, Veracyte, JUL 23, 2018, View Source/news-releases/news-release-details/veracyte-announces-second-quarter-2018-financial-results" target="_blank" title="View Source/news-releases/news-release-details/veracyte-announces-second-quarter-2018-financial-results" rel="nofollow">View Source [SID1234527818]). For the second quarter of 2018, revenue was $22.8 million, an increase of 24%, compared to $18.4 million for the second quarter of 2017. Genomic test volume was 7,686, an increase of 18% compared to the same period in 2017.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We delivered another exceptional quarter of revenue and genomic test volume growth," said Bonnie Anderson, chairman and chief executive officer of Veracyte. "We saw strong growth in our Afirma business where our deep RNA sequencing platform is enabling us to further reduce surgeries in thyroid cancer diagnosis and inform treatment decisions. We accelerated uptake of Percepta in lung cancer diagnosis, while launching our Early Access Program to address strong physician demand for Envisia – and are already leveraging crossover business opportunities with these two pulmonology products."
Second Quarter 2018 Financial Results
For the three-month period ended June 30, 2018, as compared to the second quarter of 2017:
Revenue was $22.8 million, an increase of 24%;
Genomic Test Volume was 7,686, an increase of 18%;
Gross Margin was 64%, an increase of 2%;
Operating Expenses, Excluding Cost of Revenue were $20.4 million, an increase of 13%;
Net Loss and Comprehensive Loss was ($6.2) million, an improvement of 14%;
Basic and Diluted Net Loss Per Common Share was ($0.18), an improvement of 18%;
Cash Burn1 was $3.6 million, an improvement of 28%; and
Cash and Cash Equivalents was $23.8 million at June 30, 2018.
For the six-month period ended June 30, 2018, as compared to the prior year period of 2017:
Revenue was $42.8 million, an increase of 23%;
Genomic Test Volume was 14,550, an increase of 18%;
Gross Margin was unchanged at 62%;
Operating Expenses, Excluding Cost of Revenue were $41.6 million, an increase of 16%;
Net Loss and Comprehensive Loss was ($15.4) million, an improvement of 1%;
Basic and Diluted Net Loss Per Common Share was ($0.45), an improvement of 2%; and
Cash Burn1 was $11.3 million, an improvement of 15%.
1 A reconciliation of net cash used in operating activities to cash burn has been provided in the financial statement tables included in this press release. An explanation of cash burn is also included below under the heading "Non-GAAP Financial Measures."
Second Quarter 2018 and Recent Business Highlights
Commercial Growth:
Tripled Percepta revenue for the second quarter of 2018, compared to the first quarter, with the number of physicians ordering the Percepta classifier increasing by over 50 percent during this period.
Received regulatory approval from the New York State Department of Health, enabling us to now move 100% of Afirma classifier testing to the Genomic Sequencing Classifier (GSC).
Commercially launched the Afirma Xpression Atlas, providing RNA sequencing-based insights to inform surgery and treatment decisions in patients with suspected thyroid cancer.
Booked our first biopharmaceutical service revenue of $0.5 million based on the Afirma Xpression Atlas platform.
Launched the Envisia Early Access Program to select sites across the United States in response to physician demand, further preparing for commercial expansion in 2019.
Evidence Development:
Published clinical validation data for the Afirma GSC in JAMA Surgery, demonstrating the next-generation test’s ability to help approximately 70% of patients with indeterminate thyroid nodules avoid unnecessary surgery.
Strong performance and clinical utility data for our two flagship products, the Afirma GSC and the Percepta classifier, were shared in five presentations at major endocrinology and pulmonology conferences.
Scientific Innovation:
Assembled over 2,000 patient samples to advance our field-of-injury research to fuel development of a nasal swab test for early detection of lung cancer.
Updated 2018 Financial Outlook
Veracyte is increasing its 2018 annual revenue guidance to between $87 million and $89 million, from its previously updated guidance of between $83 million and $86 million. The company is narrowing its annual cash burn guidance to between $18 million and $21 million, from between $18 million and $22 million.
Conference Call and Webcast Details
Veracyte will host a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the company’s financial results and provide a general business update. The call may be accessed as follows:
Veracyte Second Quarter 2018 Conference Call
4:30 p.m. ET Today
Website:
Dial-in number (U.S.): (855) 541-0980
International Number: (970) 315-0440
Conference ID: 7784825